Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Organon |
---|---|
Information provided by: | Organon |
ClinicalTrials.gov Identifier: | NCT00420680 |
The purpose of this study is to evaluate the safety of 2.0 mg/kg and 4.0 mg/kg sugammadex given as a reversal agent at reappearance of T2 after 0.6 mg/kg rocuronium in cardiac patients
Condition | Intervention | Phase |
---|---|---|
Anesthesia |
Drug: Sugammadex Drug: Placebo |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Multi -Center, Randomized, Parallel-Group, Placebo-Controlled, Safety Assessor-Blinded Trial, Evaluating the Safety and Efficacy of Sugammadex in Cardiac Patients |
Enrollment: | 120 |
Study Start Date: | November 2005 |
Study Completion Date: | August 2006 |
Primary Completion Date: | August 2006 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Arm 1: Experimental
Sugammadex 2.0 mg/kg
|
Drug: Sugammadex
Sugammadex, 2.0 mg/kg given as a reversal agent at reappearance of T2 after 0.6 mg/kg rocuronium
|
Arm 2: Experimental
Sugammadex 4.0 mg/kg
|
Drug: Sugammadex
Sugammadex, 4.0 mg/kg given as a reversal agent at reappearance of T2 after 0.6 mg/kg rocuronium.
|
Arm 3: Placebo Comparator
Placebo
|
Drug: Placebo
Placebo given at reappearance of T2 after 0.6 mg/kg rocuronium
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | NV Organon, part of Schering-Plough Corporation ( Study Director ) |
Study ID Numbers: | 19.4.309, EudraCT Number: 2005-002000-42 |
Study First Received: | January 10, 2007 |
Last Updated: | August 8, 2008 |
ClinicalTrials.gov Identifier: | NCT00420680 |
Health Authority: | Norway: Norwegian Medicines Agency |
Rocuronium |